SCHEMBL418622

SCHEMBL418622

COC(=O)[C@@H](NC(=O)[C@H](NCl)C1CCCCC1)C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ SLC6A3 Q01959 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ KMT2A Q03164 2/20 0.37
▸ MMP1 P03956 1/20 0.37
▸ MMP8 P22894 1/20 0.37
▸ ADAM17 P78536 1/20 0.37
▸ TSHR P16473 2/20 0.36
▸ THRB P10828 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ MMP2 P08253 4/20 0.35
▸ CNR1 P21554 2/20 0.35
▸ CNR2 P34972 2/20 0.35
▸ MMP3 P08254 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ MMP13 P45452 1/20 0.34
▸ CA12 O43570 2/20 0.34
▸ CA1 P00915 2/20 0.34
▸ CA2 P00918 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12011279 1.00 ALDH1A1 (0.39) ALDH1A1NPSR1SLC6A3SMN1; SMN2KMT2A
SCHEMBL12292107 1.00 ALDH1A1 (0.39) ALDH1A1NPSR1SLC6A3SMN1; SMN2KMT2A
SCHEMBL15247694 0.99 MMP1 (0.38) ALDH1A1NPSR1SLC6A3SMN1; SMN2KMT2A
SCHEMBL13092001 0.83 AAK1 (0.47) ALDH1A1NPSR1KMT2AMMP1MMP8
SCHEMBL12011278 0.83 AAK1 (0.47) ALDH1A1NPSR1KMT2AMMP1MMP8
SCHEMBL464172 0.83 AAK1 (0.47) ALDH1A1NPSR1KMT2AMMP1MMP8
SCHEMBL464271 0.81 AAK1 (0.48) KMT2AMMP1MMP8ADAM17CA12
SCHEMBL418389 0.80 MMP1 (0.38) ALDH1A1NPSR1SLC6A3SMN1; SMN2KMT2A
Hydrochloric Acid SCHEMBL15618895 0.79 MMP1 (0.38) ALDH1A1NPSR1SLC6A3SMN1; SMN2KMT2A
Hydrochloric Acid SCHEMBL15619093 0.79 MMP1 (0.38) ALDH1A1NPSR1SLC6A3SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140294763-A1 PEPTIDOMIMETIC PROTEASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2014-10-02 — — US disclosed
US-20140294763-A1 PEPTIDOMIMETIC PROTEASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2014-10-02 — — US disclosed
US-8529882-B2 Peptidomimetic protease inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-09-10 — — US disclosed
US-8529882-B2 Peptidomimetic protease inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-09-10 — — US disclosed
US-20120282219-A1 PEPTIDOMIMETIC PROTEASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-11-08 — — US disclosed
US-20120282219-A1 PEPTIDOMIMETIC PROTEASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-11-08 — — US disclosed
US-20120064034-A1 Peptidomimetic protease inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-15 — — US disclosed
US-20120064034-A1 Peptidomimetic protease inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140294763-A1 PEPTIDOMIMETIC PROTEASE INHIBITORS CTSC, PREP, PEPD ALDH1A1 2218/4885NPSR1 2599/4885SLC6A3 4334/4885
US-20120064034-A1 Peptidomimetic protease inhibitors CTSC, PREP, PEPD ALDH1A1 2218/4885NPSR1 2599/4885SLC6A3 4334/4885
US-20120282219-A1 PEPTIDOMIMETIC PROTEASE INHIBITORS CTSC, PEPD, PREP ALDH1A1 2639/4885NPSR1 1884/4885SLC6A3 3826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback